The global clinical trials market is projected to grow from $135.51 billion in 2026 to $176.32 billion by 2030, at a CAGR of 6.8%. Growth is fueled by advances in AI-enabled trial design, decentralized and hybrid trial platforms, and increasing demand for precision medicine and real-world evidence studies. North America leads the market, while Asia-Pacific is the fastest-growing region due to rising investment and research capacity. Key trends include AI-powered patient recruitment, remote monitoring, and greater outsourcing to contract research organizations. Strategic acquisitions and integrated technology platforms are enhancing trial efficiency and data management.
Wedbush increased its price target for Scholar Rock to $64 from $58 and kept an "Outperform" rating ahead of the FDA's September 30 decision on Scholar Rock's investigational SMA drug, apitegromab. This drug could be the first muscle-targeted therapy...
IM Cannabis Corp., a medical cannabis company operating in Israel and Germany, will conduct a 1-for-30 reverse stock split on August 27, 2026. This move aims to increase its share price, currently at $0.11, to meet the Nasdaq Capital Market's minimum...
Buckle, Inc. reported strong Q2 earnings with an EPS of $0.87, surpassing analyst estimates of $0.81, and revenue of $319.82 million, slightly above expectations. The company saw a 4.6% increase in net sales, driven by growth in both comparable-store...
KE Holdings Inc. reported Q2 2026 earnings with an EPS of $0.42, surpassing the $0.31 consensus estimate. Although revenue declined 5.7% year-over-year to about $3.60 billion, the company doubled its net income thanks to effective cost controls and o...
Strategy (MSTR) stock surged 27% over five sessions, reaching around $118, driven by a strong Bitcoin rally that pushed Bitcoin above $79,000. The overall cryptocurrency market cap rose from $2.1 trillion to $2.5 trillion, lifting crypto-related stoc...
